Related Experiment Video
Updated: Jul 5, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
Abrocitinib as a Novel Treatment for Multiple Skin Disorders: 3 Case Reports and a Scoping Review
Pingjiao Chen1, Jingyao Liang2,3, Changxing Li1
1Department of Dermatology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, People's Republic of China.
Abstract:
Janus kinase (JAK) inhibitors are increasingly being used in dermatology due to their broad potential in managing both local and systemic inflammation. More recently, abrocitinib, an oral JAK 1 inhibitor, has shown promising clinical efficacy in the treatment of various skin disorders beyond moderate to severe atopic dermatitis (AD). We firstly presented three cases, each with diagnosis of pyoderma gangrenosum (PG), livedoid vasculopathy (LV), or hidradenitis suppurativa (HS), and conducted a comprehensive scoping review of the available literature on the use of abrocitinib in the treatment of diverse skin disorders. We summarized a total of 16 skin disorders, including our cases. The results indicated that abrocitinib, whether used as monotherapy or in combination with other treatments, was effective and well-tolerated in these disorders. These findings expanded the range of diseases for which abrocitinib may serve as an alternative therapeutic choice.
More Related Videos
08:30A Novel High-Throughput Ex Vivo Ovine Skin Wound Model for Testing Emerging Antibiotics
Published on: September 16, 2022
09:29In Vivo Investigation of Antimicrobial Blue Light Therapy for Multidrug-resistant Acinetobacter baumannii Burn Infections Using Bioluminescence Imaging
Published on: April 28, 2017
Related Concept Videos
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Clinical Applications of Epidermal Stem Cells
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Abnormal Proliferation